Lupin Limited — PPTs, 15-05-2025: Investor Presentation

1. Financial Highlights:

Lupin posted net sales of ₹22,192 Cr in FY25, up 12.9% YoY, with gross margins improving to 69.2%. EBITDA increased 38.9% to ₹5,278 Cr, representing a margin of 23.8%. Net income surged 71.4% YoY to ₹3,282 Cr. Operating cash flow strengthened alongside better working capital management, leading to zero net debt. ROCE doubled to around 20%, reflecting enhanced capital efficiency. Both US and India businesses delivered solid revenue growth with margin expansion.

2. Strategic Initiatives & Growth Drivers:

The company continues to focus on complex generics, inhalation, specialty, biosimilars, and injectables, planning 100+ new product launches through FY30. Capex and R&D spend steady at ~5.2% of sales targets inhalation green-propellant innovations and biosimilar portfolio expansion globally. In India, the focus is on chronic therapies and extra-urban market expansion, supported by digital health investments. US onshoring and diversification across developed and emerging markets remain key priorities.

3. Business Developments:

Recent launches in the US include complex generics like Mirabegron, Spiriva Gx, and Pred forte Gx. Expansion in Europe through biosimilar introductions and acquisition of Aarane TM in Germany bolster Lupin’s footprint. Growth in South Africa and Philippines is supported by OTC and chronic therapy portfolios. Strengthened lab operations and Lupin Life Sciences healthcare services enhance supply chain resilience.

4. Market Position & Competitive Advantage:

Lupin ranks 3rd among US generic companies by prescriptions and 8th in India by sales. It holds leadership in respiratory inhalation markets, a strong specialty presence in Canada and Australia, and is #1 in cardiovascular segments in South Africa. Scale, geographic diversification, and a growing complex product portfolio drive competitive strength.

5. Investor Implications:

Margin improvement, robust pipeline, and global expansion indicate solid positive growth potential. Operational efficiency, quality adherence, and digital initiatives support sustainable value creation. Execution of complex launches and regulatory compliance will be critical factors to track for meeting growth objectives.